Recruiting NCT03148743
FMT in Gut aGVHD Treated
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Fecal microbiota.
- Who it may be relevant to
- Registry conditions: Acute-graft-versus-host Disease. Basic parameters: 10 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Department of Hematology of First Affiliated Hospital of Soochow University
Overview
With the stem cell transplanting increasing, patients which effected with gut GVHD were also increased. To evaluation the safety and efficacy of FMT for gut GVHD,patients with gut GVHD were recruited.
Interventions
- Biological Fecal microbiota
fecal microbiota transplantation
Primary outcome measures
- times of stool [Time frame: 24hours,48hours,72hours, 96hours,fifth day,sixth day, a week]
Secondary outcome measures (1)
- volume in milliliter of stool [Time frame: 24hours,48hours,72hours, 96hours,fifth day,sixth day, a week]
Eligibility criteria
Inclusion criteria
- gut GVHD
Exclusion criteria
- Age>60; or Age<10
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- 中国 — Suzhou
Publications
- Liu Y, Zhao Y, Qi J, Ma X, Qi X, Wu D, Xu Y. Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD. Exp Hematol Oncol. 2022 Nov 9;11(1):96. doi: 10.1186/s40164-022-00350-6. PMID 36352455
- Zhao Y, Li X, Zhou Y, Gao J, Jiao Y, Zhu B, Wu D, Qi X. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial. Front Immunol. 2021 Jun 17;12:678476. doi: 10.3389/fimmu.2021.678476. eCollection 2021. PMID 34220825
- Qi X, Li X, Zhao Y, Wu X, Chen F, Ma X, Zhang F, Wu D. Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study. Front Immunol. 2018 Sep 25;9:2195. doi: 10.3389/fimmu.2018.02195. eCollection 2018. PMID 30319644
Identifiers
NCT: NCT03148743 · FMT2017002